Objective: Testing for antibodies against hepatitis B core antigen (anti-HBc) was introduced to detect blood donors suffering from occult hepatitis B infection. Confirmation of specification of reactive results in the anti-HBc screening assay is still a challenge for blood donation services. Methods: Two different test strategies for confirmation of specification of reactive anti-HBc tests, one performed in our institute and one suggested by the German authority (Paul-Ehrlich-Institut (PEI)), were compared. The first strategy is based on one supplemental anti-HBc test, the other requires two supplemental anti-HBc tests. Results: 389 samples from 242 donors were considered. Both test strategies yielded concordant results in 117 reactive samples termed ‘true-positive' or ‘specificity confirmed', in 156 reactive samples termed ‘false-positive' or ‘specificity not confirmed', and in 99 negative samples. In 17 samples obtained from 11 donors, both test strategies gave discrepant results (‘false-positive' but ‘specificity confirmed'). In 10 of 11 donors, a real HBV infection was very unlikely, one remained unclear. 30 donors considered ‘false-positive' became negative in all anti-HBc tests after follow-up testing and thus eligible for donor re-entry. Conclusions: The test strategy suggested by the PEI yielded no additional information but induced an overestimation of HBV infections and unnecessary look-back procedures. Many anti-HBc-reactive donors can be regained after follow-up testing.

Keywords:
Hepatitis B virus, Anti-HBc, HBV DNA, Blood donor, Donor re-entry
1.
Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K: Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47:1197-1205.
2.
Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP: Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008;48:1022-1025.
3.
Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H: Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2002;100:2637-2641.
4.
Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP; Retrovirus Epidemiology Donor Study: Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003;43:696-704.
5.
Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, Weichert W, Hedges D, Seifried E: NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002;42:869-75.
6.
Dreier J, Kröger M, Diekmann J, Götting C, Kleesiek K: Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med 2004;14:97-103.
7.
Food and Drug Administration. Center for Biologics Evaluation and Research: FDA recommendations concerning testing for antibody to hepatitis B core antigen (Anti-HBc). www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommendationsforManufacturers/Memorandumto BloodEstablishments/UCM062847.pdf (last accessed October 16, 2015).
8.
O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC: Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007;47:1809-1815.
9.
Paul-Ehrlich-Institut: Bekanntmachung über die Zulassung von Arzneimitteln - Abwehr von Arzneimittelrisiken Stufe II - (Neufassung: Testung auf Antikörper gegen Hepatitis-B-Core-Antigen (anti-HBc) im Blutspendewesen) vom: 07.02.2014. Bundesanzeiger, BAnz AT 18.03.2014: B6.
10.
Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, Uchida S, Tadokoro K: Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion 2013;53:1393-1404.
11.
Wendel S, Levi JE, Biagini S, Candotti D, Allain JP: A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. Transfusion 2008;48:1602-1608.
12.
Servant-Delmas A, Chuteau C, Lefort C, Piquet Y, Chevaleyre S, Betbeze V, Delhoume M, Hantz S, Alain S, Laperche S: Two cases of transfusion-transmitted hepatitis low-endemic country before implementation of HBV nucleic acid testing. Transfusion 2013;53:291-296.
13.
Juhl D, Luhm J, Görg S, Ziemann M, Hennig H: Evaluation of algorithms for the diagnostic assessment and the reentry of blood donors who tested reactive for antibodies against hepatitis B core antigen. Transfusion 2011;51:1477-1485.
14.
Lieshout-Krikke RW, Molenaar-de Backer MW, van Swieten P, Zaaijer HL: Surface antigen-negative hepatitis B virus infection in Dutch blood donors. Eur J Clin Microbiol Infect Dis 2014;33:69-77.
15.
Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H: Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008;48:286-294.
16.
Ollier L, Laffont C, Kechkekian A, Doglio A, Giordanengo V: Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera. J Virol Methods 2008;154:206-209.
17.
Schmidt M, Nübling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK: Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 2006;91:237-243.
18.
Niederhauser C, Mansouri Taleghani B, Graziani M, Stolz M, Tinguely C, Schneider P: Blood donor screening: how to decrease the risk of transfusion-transmitted hepatitis B virus? Swiss Med Wkly 2008;138:134-141.
19.
Huzly D, Nassal M, Vorreiter J, Falcone V, Neumann-Haefelin D, Gerlich WH, Panning M: Simple confirmatory assay for anti-HBc reactivity. J Clin Virol 2011;51:283-284.
20.
Gerlich WH, Glebe D, Schüttler CG: Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat 2007;14(suppl 1): 16-21.
21.
Katz L, Strong DM, Tegtmeier G, Stramer S: Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. Transfusion 2008;48:2315-2322.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.